SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire & inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is trending strongly as its staking program sees significant adoption, with a substantial portion of tokens now locked, which the community views as a bullish indicator. Holders are rallying around its unique narrative as a 'pure belief asset' offering an alternative to traditional retirement plans, fueling widespread conviction.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after securing FDA approval for NEREUS, marking the first new motion sickness treatment in decades. The community is highly focused on the drug's significant potential beyond motion sickness, particularly its ability to address nausea associated with GLP-1 weight loss medications, which could unlock a massive market. Investors are actively discussing whether the current valuation fully reflects this pivotal regulatory success and the company's broader pipeline.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology (AFJK) is currently experiencing extreme price swings and frequent trading halts, sparking active community discussion around its highly speculative nature as a "casino play." Many traders are focusing on its ultra-low float and high borrow rates, anticipating potential short squeezes, while others caution against a perceived "Chinese mafia pump" pattern often seen in similar volatile Chinese IPOs.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is generating significant buzz in the trading community, largely driven by its exceptionally low float and high insider ownership. Many view it as the next potential 'squeeze' play, drawing strong comparisons to recent low-float SPACs like AFJK and ASPC which saw substantial upward movement. This unique structural setup fuels active discussion about its potential for rapid price action.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing high volatility as investors await an overdue FDA decision on Relacorilant for Cushing's syndrome, a key PDUFA date that passed without official news. This has ignited intense community debate, with some highlighting strong GRACE trial data and the broader pipeline, while others express concern that the delay may indicate a Complete Response Letter amidst notable trading volume and market speculation.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co

Alpha Capital Acquisition Co. is generating significant buzz due to its extremely low public float and status as a SPAC, fueling speculation about a potential parabolic surge. The community is actively discussing its 'time bomb' setup and drawing comparisons to other volatile low-float stocks, with many anticipating a short squeeze amid frequent trading halts.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amid analyst caution on its revenue outlook, largely attributed to crypto market weakness. Simultaneously, its holiday "free gift" giveaways are sparking considerable community debate, with users expressing both appreciation for small crypto rewards and frustration over app glitches. Conversations also revolve around its sensitivity to Bitcoin's price and its future as a broad fintech platform.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is trending following an eight-figure contract award to provide spacecraft docking systems for The Exploration Company's European Nyx capsule. This news, coupled with the company's significant short interest and its strategic position in the burgeoning space infrastructure and defense sectors, is fueling community speculation about a potential short squeeze and a substantial revaluation.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors eagerly await an FDA decision on its AXS-05 supplemental NDA for Alzheimer's disease agitation, viewed as a significant catalyst for an underserved market. This anticipation is fueled by consistently strong and growing prescription numbers for Auvelity in major depressive disorder, reflecting robust commercial execution. The company's expanding CNS pipeline and positive analyst sentiment continue to reinforce its perceived long-term value within the biopharmaceutical sector.

ProShares Trust - ProShares Short Bitcoin ETF

ProShares Short Bitcoin Strategy ETF

ProShares Short Bitcoin Strategy ETF ($BITI) is a focal point of market discussion as bearish sentiment on Bitcoin gains traction, with many anticipating a significant cryptocurrency pullback. The community is actively debating using inverse ETFs like BITI to either capitalize on or hedge against a potential Bitcoin correction, citing concerns over its speculative nature and "bubble" warnings from prominent investors. This reflects a prevailing view among some that Bitcoin's recent rally faces considerable downside risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galecto (NASDAQ:GLTO) Shares Down 13.3% - Time to Sell?

Galecto (NASDAQ:GLTO) Stock Price Down 13.3% - Here's Why...

Small Cap Stocks To Watch Today - November 11th

Spring Valley Acquisition, enGene, Canadian Solar, Galecto, RealReal, Daily Journal Corp. (S.C.), and Navitas Semiconductor are the seven Small Cap stocks to watch today, according to MarketBeat's...

Small Cap Stocks To Research - November 10th

Spring Valley Acquisition, Galecto, Movano, Papa John's International, Strive, Inflection Point Acquisition Corp. II, and Direxion Daily PLTR Bull 2X Shares are the seven Small Cap stocks to watch...

<ul class="summary-bullets"><li>Galecto announced the acquisition of Damora Therapeutics and a $285 million private raise backed by major biotech investors, including Viking Global, RA Capital, and a16z Bio + Health.</li><li>The deal adds Damora’s portfolio of mutant calreticulin–targeting antibody therapies for rare blood cancers, with early human trial data expected in 2027.</li><li>The acquisition positions Galecto to focus on next-generation treatments for myeloproliferative neoplasms, expanding its cancer pipeline alongside its ongoing AML drug program.</li></ul>Shares of Galecto surged nearly&nbsp;25% in premarket trading on Tuesday after the biotech firm announced the acquisition of Damora Therapeutics, a private company developing next-generation antibody drugs for rare blood cancers.<h2 class="st-heading-2">Galecto Bets Big On Blood Cancer Therapies</h2>The acquisition gives Galecto control of Damora’s pipeline of mutant calreticulin (mutCALR)-targeting therapies, including DMR-001, a monoclonal antibody that aims to treat two difficult-to-manage bone marrow cancers, which are essential thrombocythemia and myelofibrosis. The company said the drug could be “best in class,” with the potential to work across a broad range of disease-driving mutations.As part of the deal, Galecto raised $285 million in a private round that drew some of the biggest names in biotech investing, including Viking Global Investors, RA Capital Management, Wellington Management, Blackstone, BB Biotech, and Andreessen Horowitz’s a16z Bio + Health. The funding gives the company enough cash to operate well into 2029, with early human trial data for DMR-001 expected in 2027.<h2 class="st-heading-2">A New Chapter For Galecto</h2>Galecto CEO Hans Schambye called the deal a “pivotal milestone” that positions the company to accelerate next-generation treatments for blood cancers driven by mutCALR, which account for roughly 25% of essential thrombocythemia and 35% of myelofibrosis cases in the U.S.Incoming board member Peter Harwin, managing partner at Fairmount, said the combined financial and clinical resources will enable Galecto to advance DMR-001 from preclinical to human testing by mid-2026, with the goal of offering a safer, more convenient treatment option for patients.<h2 class="st-heading-2">Growing Its Cancer Pipeline</h2>Beyond Damora’s assets, Galecto said it’s also advancing its own drug, GB3226, for acute myeloid leukemia (AML). The compound will be featured at the American Society of Hematology’s annual meeting in December, with an FDA filing expected in early 2026 to begin human testing.<h2 class="st-heading-2">Stocktwits Users Eye Multi-Day Rally</h2>On Stocktwits, retail sentiment for Galecto was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:962/134;" src="https://news.stocktwits-cdn.com/glto_ss_jpg_87be36e195.webp" alt="glto ss.jpg" width="962" height="134"><figcaption>GLTO sentiment and message volume as of November 11 | Source: Stocktwits</figcaption></figure>One user speculated that Galecto’s stock could turn into a “multi-day runner,” hinting at continued momentum after its sharp surge.<stembedurl>https://stocktwits.com/Bcscoatings/message/635686140</stembedurl>Another user was far more bullish, predicting the stock could hit $50 next and even climb toward $150.<stembedurl>https://stocktwits.com/BearBullRunner/message/635681400</stembedurl><a href="https://stocktwits.com/symbol/GLTO">Galecto’s stock</a> has surged by more than 270% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Galecto Biotech logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Galecto Stock Surges Premarket After Damora Acquisition — Retail Bulls Predict Another Massive Rally

Galecto announced the acquisition of Damora Therapeutics and a $285 million private raise backed by major biotech investors, including Viking Global, RA Capital, and a16z Bio + Health.

Equity

Shares of biotechnology company Galecto, Inc. (GLTO) soared 632% in the pre-market session on Tuesday. The stock is on track to hit over two-year highs.Galecto is focused on developing treatments for oncological and liver diseases. Its pipeline consists of drug candidates that target cancer and fibrosis signaling pathways, including GB1211 for the treatment of liver cirrhosis, GB1211 in combination with a checkpoint inhibitor for various oncology indications, and GB3226 for multiple genetic subsets of Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GLTO">GLTO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1362/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_8_17_12_AM_png_631ad32651.webp" alt="GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1362" height="124"><figcaption>GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that this is a pump-and-dump move.<stembedurl>https://stocktwits.com/moneytra1n/message/631281671</stembedurl>Another believes that the rally could be short-lived.<stembedurl>https://stocktwits.com/come_litaliano/message/631283183</stembedurl>In August, Galecto CEO Hans Schambye announced that the company is looking forward to submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the first quarter of 2026 for its lead program, GB3226. Preclinical data support the therapeutic potential of the candidate as a monotherapy and in combination to address the menin-resistant population within AML, the company said.Galecto ended the second quarter with approximately $10.2 million in cash and cash equivalents. Last month, it said that it expects this amount to be sufficient to fund operating expenses and capital requirements into 2026, including the submission of the investigational new drug application for GB3226.The company also noted that it would require substantial additional capital to finance its operations, including future clinical development of its GB3226 and GB1211 programs.GLTO stock is down by 20% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jlr-begins-phased-restart-of-operations-more-than-a-month-after-cyber-incident/ch6P7elR3WM">JLR Begins Phased Restart Of Operations More Than A Month After Cyber Incident</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GLTO Stock Rises A Whopping 632% Pre-Market, But Retail Investors Remain Cautious

Galecto is focused on developing treatments for oncological and liver diseases.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

GLTO
Galecto Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GLTO News

GLTOGalecto Inc